BIOMAT Database Logo BIOMAT Database Logo

Diabetes Induced by Immune Checkpoint Inhibitors (ICIs). 2023

Bruno Vergès
Endocrinology-Diabetology Department, University-Hospital and INSERM CRI 866, Medicine University, 21000 Dijon, France. Electronic address: bruno.verges@chu-dijon.fr.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000082082 Immune Checkpoint Inhibitors Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies. CTLA-4 Inhibitor,CTLA-4 Inhibitors,Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor,Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors,Immune Checkpoint Blockade,Immune Checkpoint Blockers,Immune Checkpoint Inhibition,Immune Checkpoint Inhibitor,PD-1 Inhibitor,PD-1 Inhibitors,PD-1-PD-L1 Blockade,PD-L1 Inhibitor,PD-L1 Inhibitors,Programmed Cell Death Protein 1 Inhibitor,Programmed Cell Death Protein 1 Inhibitors,Programmed Death-Ligand 1 Inhibitors,Blockade, PD-1-PD-L1,CTLA 4 Inhibitor,CTLA 4 Inhibitors,Checkpoint Blockade, Immune,Checkpoint Blockers, Immune,Checkpoint Inhibition, Immune,Checkpoint Inhibitor, Immune,Checkpoint Inhibitors, Immune,Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor,Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors,Inhibitor, PD-1,PD 1 Inhibitor,PD 1 Inhibitors,PD 1 PD L1 Blockade,PD L1 Inhibitor,PD L1 Inhibitors,Programmed Death Ligand 1 Inhibitors

Related Publications

Bruno Vergès
Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
January 2020, Advances in experimental medicine and biology,
Bruno Vergès
Immune checkpoint inhibitors (ICIs)-related ocular myositis.
May 2020, Neuromuscular disorders : NMD,
Bruno Vergès
Diabetes mellitus induced by immune checkpoint inhibitors.
January 2021, Diabetes/metabolism research and reviews,
Bruno Vergès
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
April 2022, Cell communication and signaling : CCS,
Bruno Vergès
Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency.
December 2023, Translational oncology,
Bruno Vergès
Type 1 diabetes induced by immune checkpoint inhibitors.
November 2020, Chinese medical journal,
Bruno Vergès
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.
January 2022, Cancer cell international,
Bruno Vergès
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
January 2018, Journal of UOEH,
Bruno Vergès
Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
September 2021, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
Bruno Vergès
[Endocrinopathies induced by immune checkpoint inhibitors].
January 2018, Revue medicale suisse,
Copied contents to your clipboard!